Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study.
Identifieur interne : 000207 ( Main/Corpus ); précédent : 000206; suivant : 000208Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study.
Auteurs : David P. Hudesman ; Soumya D. Chakravarty ; Bruno Emond ; Lorie A. Ellis ; Patrick Lefebvre ; Kay Sadik ; Jose U. ScherSource :
- BMC rheumatology [ 2520-1026 ] ; 2020.
Abstract
Background
Chronic inflammatory diseases (CIDs; ankylosing spondylitis [AS], psoriatic arthritis [PsA], psoriasis [PsO], or rheumatoid arthritis [RA]) and inflammatory bowel disease (IBD; Crohn's disease and ulcerative colitis) are associated with substantial economic burden. The relative increased costs among patients with CIDs and concomitant IBD compared to those without IBD is an important consideration when deciding on the clinical management of patient symptoms. Given the increasing use of novel agents for the treatment of CIDs, including those that may increase the risk of IBD in patients with CIDs, the objective of the study was to describe the incidence of IBD and to quantify healthcare resource utilization (HRU) and costs associated with IBD among patients with CIDs.
Methods
The IBM MarketScan® Research Databases (1/2010-7/2017) were used to identify adult patients with ≥2 claims with a diagnosis of either AS/PsA/PsO/RA (index date was a random claim for AS/PsA/PsO/RA). The one-year incidence rate of IBD was calculated following the index date. HRU and healthcare costs were compared between patients developing and not developing IBD in the year following the index date, adjusting for baseline characteristics.
Results
A total of 537,450 patients with CIDs (mean age = 54.0 years; 63.1% female) were included in the study. The 1-year incidence rate of IBD was 0.52% (range = 0.39% in patients with PsO but without PsA to 1.73% in patients with AS). Patients who developed IBD (
Conclusion
Higher HRU and costs were observed in patients with concomitant CID and IBD compared to patients with CID alone. Consideration should be given to treatment decisions that adequately manage CID and IBD to ensure optimal clinical and economic outcomes.
DOI: 10.1186/s41927-020-0115-2
PubMed: 32266326
PubMed Central: PMC7114816
Links to Exploration step
pubmed:32266326Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study.</title><author><name sortKey="Hudesman, David P" sort="Hudesman, David P" uniqKey="Hudesman D" first="David P" last="Hudesman">David P. Hudesman</name><affiliation><nlm:affiliation>1NYU Langone Health, 240 East 38th Street, 23rd Floor, New York, NY 10016 USA.</nlm:affiliation></affiliation></author><author><name sortKey="Chakravarty, Soumya D" sort="Chakravarty, Soumya D" uniqKey="Chakravarty S" first="Soumya D" last="Chakravarty">Soumya D. Chakravarty</name><affiliation><nlm:affiliation>Janssen Scientific Affairs, LLC, 800 Ridgeview Drive, Horsham, PA 19044 USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>3Drexel University College of Medicine, Philadelphia, PA USA.</nlm:affiliation></affiliation></author><author><name sortKey="Emond, Bruno" sort="Emond, Bruno" uniqKey="Emond B" first="Bruno" last="Emond">Bruno Emond</name><affiliation><nlm:affiliation>Analysis Group, Inc., Montréal, Québec Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Ellis, Lorie A" sort="Ellis, Lorie A" uniqKey="Ellis L" first="Lorie A" last="Ellis">Lorie A. Ellis</name><affiliation><nlm:affiliation>Janssen Scientific Affairs, LLC, 800 Ridgeview Drive, Horsham, PA 19044 USA.</nlm:affiliation></affiliation></author><author><name sortKey="Lefebvre, Patrick" sort="Lefebvre, Patrick" uniqKey="Lefebvre P" first="Patrick" last="Lefebvre">Patrick Lefebvre</name><affiliation><nlm:affiliation>Analysis Group, Inc., Montréal, Québec Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Sadik, Kay" sort="Sadik, Kay" uniqKey="Sadik K" first="Kay" last="Sadik">Kay Sadik</name><affiliation><nlm:affiliation>Janssen Scientific Affairs, LLC, 800 Ridgeview Drive, Horsham, PA 19044 USA.</nlm:affiliation></affiliation></author><author><name sortKey="Scher, Jose U" sort="Scher, Jose U" uniqKey="Scher J" first="Jose U" last="Scher">Jose U. Scher</name><affiliation><nlm:affiliation>1NYU Langone Health, 240 East 38th Street, 23rd Floor, New York, NY 10016 USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32266326</idno><idno type="pmid">32266326</idno><idno type="doi">10.1186/s41927-020-0115-2</idno><idno type="pmc">PMC7114816</idno><idno type="wicri:Area/Main/Corpus">000207</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000207</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study.</title><author><name sortKey="Hudesman, David P" sort="Hudesman, David P" uniqKey="Hudesman D" first="David P" last="Hudesman">David P. Hudesman</name><affiliation><nlm:affiliation>1NYU Langone Health, 240 East 38th Street, 23rd Floor, New York, NY 10016 USA.</nlm:affiliation></affiliation></author><author><name sortKey="Chakravarty, Soumya D" sort="Chakravarty, Soumya D" uniqKey="Chakravarty S" first="Soumya D" last="Chakravarty">Soumya D. Chakravarty</name><affiliation><nlm:affiliation>Janssen Scientific Affairs, LLC, 800 Ridgeview Drive, Horsham, PA 19044 USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>3Drexel University College of Medicine, Philadelphia, PA USA.</nlm:affiliation></affiliation></author><author><name sortKey="Emond, Bruno" sort="Emond, Bruno" uniqKey="Emond B" first="Bruno" last="Emond">Bruno Emond</name><affiliation><nlm:affiliation>Analysis Group, Inc., Montréal, Québec Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Ellis, Lorie A" sort="Ellis, Lorie A" uniqKey="Ellis L" first="Lorie A" last="Ellis">Lorie A. Ellis</name><affiliation><nlm:affiliation>Janssen Scientific Affairs, LLC, 800 Ridgeview Drive, Horsham, PA 19044 USA.</nlm:affiliation></affiliation></author><author><name sortKey="Lefebvre, Patrick" sort="Lefebvre, Patrick" uniqKey="Lefebvre P" first="Patrick" last="Lefebvre">Patrick Lefebvre</name><affiliation><nlm:affiliation>Analysis Group, Inc., Montréal, Québec Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Sadik, Kay" sort="Sadik, Kay" uniqKey="Sadik K" first="Kay" last="Sadik">Kay Sadik</name><affiliation><nlm:affiliation>Janssen Scientific Affairs, LLC, 800 Ridgeview Drive, Horsham, PA 19044 USA.</nlm:affiliation></affiliation></author><author><name sortKey="Scher, Jose U" sort="Scher, Jose U" uniqKey="Scher J" first="Jose U" last="Scher">Jose U. Scher</name><affiliation><nlm:affiliation>1NYU Langone Health, 240 East 38th Street, 23rd Floor, New York, NY 10016 USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">BMC rheumatology</title><idno type="eISSN">2520-1026</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>Background</b></p><p>Chronic inflammatory diseases (CIDs; ankylosing spondylitis [AS], psoriatic arthritis [PsA], psoriasis [PsO], or rheumatoid arthritis [RA]) and inflammatory bowel disease (IBD; Crohn's disease and ulcerative colitis) are associated with substantial economic burden. The relative increased costs among patients with CIDs and concomitant IBD compared to those without IBD is an important consideration when deciding on the clinical management of patient symptoms. Given the increasing use of novel agents for the treatment of CIDs, including those that may increase the risk of IBD in patients with CIDs, the objective of the study was to describe the incidence of IBD and to quantify healthcare resource utilization (HRU) and costs associated with IBD among patients with CIDs.</p></div><div type="abstract" xml:lang="en"><p><b>Methods</b></p><p>The IBM MarketScan® Research Databases (1/2010-7/2017) were used to identify adult patients with ≥2 claims with a diagnosis of either AS/PsA/PsO/RA (index date was a random claim for AS/PsA/PsO/RA). The one-year incidence rate of IBD was calculated following the index date. HRU and healthcare costs were compared between patients developing and not developing IBD in the year following the index date, adjusting for baseline characteristics.</p></div><div type="abstract" xml:lang="en"><p><b>Results</b></p><p>A total of 537,450 patients with CIDs (mean age = 54.0 years; 63.1% female) were included in the study. The 1-year incidence rate of IBD was 0.52% (range = 0.39% in patients with PsO but without PsA to 1.73% in patients with AS). Patients who developed IBD (</p></div><div type="abstract" xml:lang="en"><p><b>Conclusion</b></p><p>Higher HRU and costs were observed in patients with concomitant CID and IBD compared to patients with CID alone. Consideration should be given to treatment decisions that adequately manage CID and IBD to ensure optimal clinical and economic outcomes.</p></div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32266326</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2520-1026</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>BMC rheumatology</Title><ISOAbbreviation>BMC Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study.</ArticleTitle><Pagination><MedlinePgn>16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s41927-020-0115-2</ELocationID><Abstract><AbstractText Label="Background" NlmCategory="UNASSIGNED">Chronic inflammatory diseases (CIDs; ankylosing spondylitis [AS], psoriatic arthritis [PsA], psoriasis [PsO], or rheumatoid arthritis [RA]) and inflammatory bowel disease (IBD; Crohn's disease and ulcerative colitis) are associated with substantial economic burden. The relative increased costs among patients with CIDs and concomitant IBD compared to those without IBD is an important consideration when deciding on the clinical management of patient symptoms. Given the increasing use of novel agents for the treatment of CIDs, including those that may increase the risk of IBD in patients with CIDs, the objective of the study was to describe the incidence of IBD and to quantify healthcare resource utilization (HRU) and costs associated with IBD among patients with CIDs.</AbstractText><AbstractText Label="Methods" NlmCategory="UNASSIGNED">The IBM MarketScan® Research Databases (1/2010-7/2017) were used to identify adult patients with ≥2 claims with a diagnosis of either AS/PsA/PsO/RA (index date was a random claim for AS/PsA/PsO/RA). The one-year incidence rate of IBD was calculated following the index date. HRU and healthcare costs were compared between patients developing and not developing IBD in the year following the index date, adjusting for baseline characteristics.</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">A total of 537,450 patients with CIDs (mean age = 54.0 years; 63.1% female) were included in the study. The 1-year incidence rate of IBD was 0.52% (range = 0.39% in patients with PsO but without PsA to 1.73% in patients with AS). Patients who developed IBD (<i>N</i> = 2778) had significantly higher rates of inpatient, outpatient, and emergency room visits (incidence rate ratios [IRR] = 2.91, 1.35, 1.81; all <i>P</i> < 0.0001), compared to patients without IBD (<i>N</i> = 534,672). Patients who developed IBD had $18,500 (<i>P</i> < 0.0001) higher total costs per year, including $15,121 (<i>P</i> < 0.0001) higher medical costs and $3380 higher pharmacy costs (<i>P</i> < 0.0001).</AbstractText><AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Higher HRU and costs were observed in patients with concomitant CID and IBD compared to patients with CID alone. Consideration should be given to treatment decisions that adequately manage CID and IBD to ensure optimal clinical and economic outcomes.</AbstractText><CopyrightInformation>© The Author(s) 2020.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hudesman</LastName><ForeName>David P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>1NYU Langone Health, 240 East 38th Street, 23rd Floor, New York, NY 10016 USA.</Affiliation><Identifier Source="ISNI">0000 0004 1936 8753</Identifier><Identifier Source="GRID">grid.137628.9</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chakravarty</LastName><ForeName>Soumya D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Janssen Scientific Affairs, LLC, 800 Ridgeview Drive, Horsham, PA 19044 USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>3Drexel University College of Medicine, Philadelphia, PA USA.</Affiliation><Identifier Source="ISNI">0000 0001 2181 3113</Identifier><Identifier Source="GRID">grid.166341.7</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emond</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Analysis Group, Inc., Montréal, Québec Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellis</LastName><ForeName>Lorie A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Janssen Scientific Affairs, LLC, 800 Ridgeview Drive, Horsham, PA 19044 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lefebvre</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Analysis Group, Inc., Montréal, Québec Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadik</LastName><ForeName>Kay</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Janssen Scientific Affairs, LLC, 800 Ridgeview Drive, Horsham, PA 19044 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scher</LastName><ForeName>Jose U</ForeName><Initials>JU</Initials><AffiliationInfo><Affiliation>1NYU Langone Health, 240 East 38th Street, 23rd Floor, New York, NY 10016 USA.</Affiliation><Identifier Source="ISNI">0000 0004 1936 8753</Identifier><Identifier Source="GRID">grid.137628.9</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Rheumatol</MedlineTA><NlmUniqueID>101738571</NlmUniqueID><ISSNLinking>2520-1026</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ankylosing spondylitis</Keyword><Keyword MajorTopicYN="N">Crohn’s disease</Keyword><Keyword MajorTopicYN="N">Healthcare costs</Keyword><Keyword MajorTopicYN="N">Healthcare resource utilization</Keyword><Keyword MajorTopicYN="N">Inflammatory bowel disease</Keyword><Keyword MajorTopicYN="N">Psoriasis</Keyword><Keyword MajorTopicYN="N">Psoriatic arthritis</Keyword><Keyword MajorTopicYN="N">Rheumatoid arthritis</Keyword><Keyword MajorTopicYN="N">Ulcerative colitis</Keyword></KeywordList><CoiStatement>Competing interestsBE and PL are employees of Analysis Group, Inc., a consulting company which provided paid consulting services to Janssen Scientific Affairs, LLC for the conduct of this study. SDC, LAE, and KS are employees of Janssen Scientific Affairs, LLC and shareholders of Johnson & Johnson, of which Janssen Scientific Affairs, LLC is a wholly-owned subsidiary. DPH reports the following affiliations: Janssen (consulting), Takeda (consulting), AbbVie (consulting), Salix (consulting), and Pfizer (consulting and research support). JUS reports the following affiliations: Janssen (consulting), UCB (consulting), Novartis (consulting and research support), Amgen (consulting and research support [via NIH Target]), and Pfizer (research support).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>08</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>01</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32266326</ArticleId><ArticleId IdType="doi">10.1186/s41927-020-0115-2</ArticleId><ArticleId IdType="pii">115</ArticleId><ArticleId IdType="pmc">PMC7114816</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Res Social Adm Pharm. 2017 May - Jun;13(3):530-538</Citation><ArticleIdList><ArticleId IdType="pubmed">27263802</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med. 2011 Nov 15;9:122</Citation><ArticleIdList><ArticleId IdType="pubmed">22082127</ArticleId></ArticleIdList></Reference><Reference><Citation>J Occup Environ Med. 2008 Nov;50(11):1261-72</Citation><ArticleIdList><ArticleId IdType="pubmed">19001952</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2016 Jul 28;375(4):345-56</Citation><ArticleIdList><ArticleId IdType="pubmed">27299809</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2010 Mar;105(3):501-23; quiz 524</Citation><ArticleIdList><ArticleId IdType="pubmed">20068560</ArticleId></ArticleIdList></Reference><Reference><Citation>Best Pract Res Clin Rheumatol. 2006 Jun;20(3):451-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16777576</ArticleId></ArticleIdList></Reference><Reference><Citation>J Crohns Colitis. 2015 Sep;9(9):697-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26079725</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ Open. 2019 Jun 19;9(6):e027495</Citation><ArticleIdList><ArticleId IdType="pubmed">31221884</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gastroenterol. 2018 Mar;53(3):305-353</Citation><ArticleIdList><ArticleId IdType="pubmed">29429045</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol Suppl. 2010 May;85:2-10</Citation><ArticleIdList><ArticleId IdType="pubmed">20436161</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheumatol. 2016 Feb;68(2):282-98</Citation><ArticleIdList><ArticleId IdType="pubmed">26401991</ArticleId></ArticleIdList></Reference><Reference><Citation>Inflamm Bowel Dis. 2020 Jan 1;26(1):1-10</Citation><ArticleIdList><ArticleId IdType="pubmed">31112238</ArticleId></ArticleIdList></Reference><Reference><Citation>Dig Dis Sci. 2016 Jun;61(6):1772-4</Citation><ArticleIdList><ArticleId IdType="pubmed">26728477</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2013 Jul;72(7):1200-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22941766</ArticleId></ArticleIdList></Reference><Reference><Citation>Cytokine. 2015 Jun;73(2):342-50</Citation><ArticleIdList><ArticleId IdType="pubmed">25585875</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Immunol. 2019 Sep;206:3-8</Citation><ArticleIdList><ArticleId IdType="pubmed">29621613</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2014 May;14(5):329-42</Citation><ArticleIdList><ArticleId IdType="pubmed">24751956</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2015 Dec 24;373(26):2534-48</Citation><ArticleIdList><ArticleId IdType="pubmed">26699169</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2011 Mar 15;173(6):676-82</Citation><ArticleIdList><ArticleId IdType="pubmed">21330339</ArticleId></ArticleIdList></Reference><Reference><Citation>J Eur Acad Dermatol Venereol. 2009 May;23(5):561-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19207663</ArticleId></ArticleIdList></Reference><Reference><Citation>J Crohns Colitis. 2014 Oct;8(10):1281-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24662394</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Med Res Opin. 2019 Oct;35(10):1751-1759</Citation><ArticleIdList><ArticleId IdType="pubmed">31106607</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2015 Jan;74(1):65-73</Citation><ArticleIdList><ArticleId IdType="pubmed">23999006</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Genet. 2011 Aug;7(8):e1002254</Citation><ArticleIdList><ArticleId IdType="pubmed">21852963</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology Res. 2018 Jun;11(3):174-188</Citation><ArticleIdList><ArticleId IdType="pubmed">29915627</ArticleId></ArticleIdList></Reference><Reference><Citation>Gut. 2012 Dec;61(12):1693-700</Citation><ArticleIdList><ArticleId IdType="pubmed">22595313</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2005 Sep;129(3):827-36</Citation><ArticleIdList><ArticleId IdType="pubmed">16143122</ArticleId></ArticleIdList></Reference><Reference><Citation>Dig Dis Sci. 2012 Dec;57(12):3080-91</Citation><ArticleIdList><ArticleId IdType="pubmed">22790905</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomed Res Int. 2013;2013:983902</Citation><ArticleIdList><ArticleId IdType="pubmed">23971052</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2018 Apr;113(4):481-517</Citation><ArticleIdList><ArticleId IdType="pubmed">29610508</ArticleId></ArticleIdList></Reference><Reference><Citation>Inflamm Bowel Dis. 2011 Jul;17(7):1603-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21053357</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2008 Dec;135(6):1907-13</Citation><ArticleIdList><ArticleId IdType="pubmed">18854185</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/WillowV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000207 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000207 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= WillowV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32266326
|texte= Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32266326" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a WillowV1
| This area was generated with Dilib version V0.6.37. |  |